Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05014646 · ClinicalTrials.gov registry record · Phase 2
Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients
A Phase 2 study of Smoldering Plasma Cell Myeloma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 27
- Enrollment target
- 4
- Study locations
NCT05014646: Active Phase 2 study of Smoldering Plasma Cell Myeloma, sponsored by City of Hope Medical Center.
NCT05014646 is a Phase 2 study of Smoldering Plasma Cell Myeloma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 27 participants, below the 136-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (80% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05014646, a Phase 2 study of Smoldering Plasma Cell Myeloma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 27 participants
- Enrollment target
- 4
- Study locations
Study Summary
This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and European decent.
Conditions Studied
Interventions
- DRUG Cholestyramine
- DRUG Leflunomide
Study Locations (4)
California
- City of Hope Medical Center - Duarte
Michigan
- Wayne State University/Karmanos Cancer Institute - Detroit
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Atrium Health University City/LCI-University - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-03-07 |
| Est. Completion | 2027-01-16 |
| Phase | Phase 2 |
What the registry record for NCT05014646 still lists
NCT05014646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 27 participants, a relatively small participant target, below the 136-participant average among 9 other Smoldering Plasma Cell Myeloma trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Smoldering Plasma Cell Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Cholestyramine is the first listed.
NCT05014646 reports a single indexed study location in California, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT05014646 about?
NCT05014646 is a clinical study titled "Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients". This phase II trial studies the effects of leflunomide in treating African-American and European-American patients with high-risk smoldering multiple myeloma. Leflunomide is used to decrease the body's immune response and may delay the symptoms of multiple myeloma in patients of African-American and...
What is the current status of trial NCT05014646?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 27 participants. The study started on 2022-03-07. Estimated completion is 2027-01-16.
What conditions does trial NCT05014646 study?
This clinical trial studies the following conditions: Smoldering Plasma Cell Myeloma.
What interventions are being tested in trial NCT05014646?
The interventions under investigation include: Cholestyramine (DRUG), Leflunomide (DRUG).
Who is sponsoring clinical trial NCT05014646?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05014646 being conducted?
This trial has 4 study locations across California, Michigan, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoldering Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05014646's enrollment target sits among peer trials
27 7th of 9 higher than 3 of 9 other Smoldering Plasma Cell Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Smoldering Plasma Cell Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Iberdomide Alone or in Combination With Dexamethasone for the Treatment of Intermediate- or High-Risk Smoldering Multiple Myeloma
RECRUITING · Phase 2
-
Isatuximab With or Without Lenalidomide in Patients With High Risk Smoldering Multiple Myeloma (ISAMAR)
ACTIVE NOT RECRUITING · Phase 2
-
Observational Prospective Research Study In Monoclonal Gammopathies leadINg to Myeloma
RECRUITING
-
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma
RECRUITING · Phase 3
-
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
RECRUITING · NA
-
Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00912041 · 27 participants · NA
BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- NCT02847559 · 27 participants · Phase 2
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
- NCT03380195 · 27 participants · NA
Effects of Watermelon Juice on Heart Rate Recovery and Post-exercise Muscle Soreness
- NCT03384238 · 27 participants · Phase 1
Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI